Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ichigotani, Y.
Right arrow Articles by Matsuda, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichigotani, Y.
Right arrow Articles by Matsuda, S.
[Cancer Research 62, 2215-2219, April 15, 2002]
© 2002 American Association for Cancer Research


Advances in Brief

Forced Expression of NESH Suppresses Motility and Metastatic Dissemination of Malignant Cells1

Yasukatu Ichigotani2, Shouichi Yokozaki2, Yoshihide Fukuda, Michinari Hamaguchi and Satoru Matsuda2,3

Department of Molecular Pathogenesis [Y. I., M. H., S. M.], and Second Department of Internal Medicine [S. Y., Y. F.], Nagoya University School of Medicine, Nagoya 466-8550, Japan

To characterize the function of a novel Src homology 3 (SH3) adapter proteintermed NESH, we have established transfectants stably expressing NESH.We observed that every clone of NESH transfectants caused a marked reduction in motility, although the clones exhibited no significant differences in intrinsic cell growth compared with the control cells in vitro. The NESH transfectants also exhibited significant reduction in tumor metastatic potential in vivo. We found that NESH expression is frequently lost in invasive cancer cell lines despite its ubiquitous expression in normal tissues. The SH3 domain of NESH seems to interact with p21-activated kinase (PAK), which is involved in regulation of cell motility. Furthermore, a significant decrease in PAK phosphorylation at 402Thr was found in NESH transfectants. Taken together, these results suggest that NESH inhibits ectopic metastasis of tumor cells as well as cell migration through interaction with intracellular molecules such as PAK that are essential for cell motility.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Kano, N. Miyajima, S. Fukuda, and S. Hatakeyama
Tripartite Motif Protein 32 Facilitates Cell Growth and Migration via Degradation of Abl-Interactor 2
Cancer Res., July 15, 2008; 68(14): 5572 - 5580.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Matsuda, S. Yokozaki, H. Yoshida, Y. Kitagishi, N. Shirafuji, and N. Okumura
Insulin receptor substrate protein 53 (IRSp53) as a binding partner of antimetastasis molecule NESH, a member of Abelson interactor protein family
Ann. Onc., July 1, 2008; 19(7): 1356 - 1357.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.